8 research outputs found
ΠΡΠΎΠ±Π»Π΅ΠΌΠ° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ
The problem of systemic scleroderma (SSD) activity enters into the view of standardized patient examination and it is important for choosing a therapeutic complex, for determining the dose of drugs, and for monitoring therapy. Great difficulties in the determination of activity in SSD are caused by the pathogenetic and morphogenetic features of the disease. It should be emphasized that there are no clearly defined exacerbation and remission periods. It is difficult to differentiate the potentially reversible inflammatory changes determining the activity of SSD from the irreversible fibrous changes characterizing the severity of the disease. The laboratory parameters of inflammatory activity are also of little informative value. The complicated problem of activity in SSD is to be further investigated both to improve and modify existing indices and to search for a common specific marker and/or key pathogenetically and clinically relevant markers of disease activity.ΠΡΠΎΠ±Π»Π΅ΠΌΠ° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ (Π‘Π‘Π) Π½Π΅ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ²ΡΠ·Π°Π½Π° ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΠ΅ΠΉ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈ Π²Π°ΠΆΠ½Π° Π΄Π»Ρ Π²ΡΠ±ΠΎΡΠ° Π»Π΅ΡΠ΅Π±Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ°, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π΄ΠΎΠ·Ρ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠΎΠ»ΡΡΠΈΠ΅ ΡΡΡΠ΄Π½ΠΎΡΡΠΈ Π² ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈ Π‘Π‘Π ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΠΌΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° ΠΈ ΠΌΠΎΡΡΠΎΠ³Π΅Π½Π΅Π·Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π‘Π»Π΅Π΄ΡΠ΅Ρ ΠΏΠΎΠ΄ΡΠ΅ΡΠΊΠ½ΡΡΡ, ΡΡΠΎ ΠΏΡΠΈ Π‘Π‘Π Π½Π΅Ρ ΡΠ΅ΡΠΊΠΎ ΠΎΡΠ΅ΡΡΠ΅Π½Π½ΡΡ
ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΎΠ² ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΡ ΠΈ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ. Π Π°Π·Π³ΡΠ°Π½ΠΈΡΠΈΡΡ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΠΎΠ±ΡΠ°ΡΠΈΠΌΡΠ΅ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ, ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΠΈΠ΅ Β«Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΒ» Π‘Π‘Π, ΠΎΡ Π½Π΅ΠΎΠ±ΡΠ°ΡΠΈΠΌΡΡ
ΡΠΈΠ±ΡΠΎΠ·Π½ΡΡ
, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΡ
ΡΡΠΆΠ΅ΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΡΠ»ΠΎΠΆΠ½ΠΎ. ΠΠ°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ°ΠΊΠΆΠ΅ ΠΌΠ°Π»ΠΎ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½Ρ. ΠΠ΅ΠΏΡΠΎΡΡΠ°Ρ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈ Π‘Π‘Π ΠΏΠΎΠ΄Π»Π΅ΠΆΠΈΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΌΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΊΠ°ΠΊ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΈΠΌΠ΅ΡΡΠΈΡ
ΡΡ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ², ΡΠ°ΠΊ ΠΈ ΠΏΠΎΠΈΡΠΊΠ° Π΅Π΄ΠΈΠ½ΠΎΠ³ΠΎ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ/ΠΈΠ»ΠΈ Β«ΠΊΠ»ΡΡΠ΅Π²ΡΡ
Β» ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ
ΠΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π°ΠΊΡΠΎΠ²Π΅Π³ΠΈΠ½Π° ΠΏΡΠΈ ΠΎΡΠ°Π³ΠΎΠ²ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ
ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ
Up to now, it is difficult to determine systemic scleroderma (SSD) activity because of the lack of validated tools to estimate changes in the pathological process. Attempts have been made to develop unified activity assessing methods for many years. The indices proposed by the European SSD Group are most popular today. This paper gives the results of using this index in a cohort of Russian patients.ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ (Π‘Π‘Π) Π΄ΠΎ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π·Π°ΡΡΡΠ΄Π½Π΅Π½ΠΎ ΠΈΠ·-Π·Π° ΠΎΡΡΡΡΡΡΠ²ΠΈΡ Π²Π°Π»ΠΈΠ΄ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠΎΠ² Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°. Π ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΌΠ½ΠΎΠ³ΠΈΡ
Π»Π΅Ρ ΠΏΡΠ΅Π΄ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡΡΡ ΠΏΠΎΠΏΡΡΠΊΠΈ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΎΡΠ΅Π½ΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠΏΡΠ»ΡΡΠ½ΡΠΌΠΈ Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ ΡΠ²Π»ΡΡΡΡΡ ΠΈΠ½Π΄Π΅ΠΊΡΡ, ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΡΠ΅ Π΅Π²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ ΠΏΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π‘Π‘Π. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΡΡΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° Ρ ΠΊΠΎΠ³ΠΎΡΡΡ ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
The problem of activity in systemic scleroderma
The problem of systemic scleroderma (SSD) activity enters into the view of standardized patient examination and it is important for choosing a therapeutic complex, for determining the dose of drugs, and for monitoring therapy. Great difficulties in the determination of activity in SSD are caused by the pathogenetic and morphogenetic features of the disease. It should be emphasized that there are no clearly defined exacerbation and remission periods. It is difficult to differentiate the potentially reversible inflammatory changes determining the activity of SSD from the irreversible fibrous changes characterizing the severity of the disease. The laboratory parameters of inflammatory activity are also of little informative value. The complicated problem of activity in SSD is to be further investigated both to improve and modify existing indices and to search for a common specific marker and/or key pathogenetically and clinically relevant markers of disease activity
Use of the international systemic scleroderma activity index
Up to now, it is difficult to determine systemic scleroderma (SSD) activity because of the lack of validated tools to estimate changes in the pathological process. Attempts have been made to develop unified activity assessing methods for many years. The indices proposed by the European SSD Group are most popular today. This paper gives the results of using this index in a cohort of Russian patients